CODX Operating Margin from 2010 to 2025

CODX Stock  USD 0.28  0  1.50%   
Co Diagnostics Operating Profit Margin yearly trend continues to be fairly stable with very little volatility. Operating Profit Margin will likely drop to -10.75 in 2025.
Check Co Diagnostics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Co Diagnostics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 18 M or Selling General Administrative of 17 M, as well as many indicators such as Price To Sales Ratio of 5.52, Dividend Yield of 0.0 or PTB Ratio of 0.4. CODX financial statements analysis is a perfect complement when working with Co Diagnostics Valuation or Volatility modules.
  
Build AI portfolio with CODX Stock
Check out the analysis of Co Diagnostics Correlation against competitors.
For more information on how to buy CODX Stock please use our How to Invest in Co Diagnostics guide.

Latest Co Diagnostics' Operating Margin Growth Pattern

Below is the plot of the Operating Profit Margin of Co Diagnostics over the last few years. It is Co Diagnostics' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Co Diagnostics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (170.10) %10 Years Trend
Slightly volatile
   Operating Profit Margin   
       Timeline  

CODX Operating Margin Regression Statistics

Arithmetic Mean(161.21)
Geometric Mean35.11
Coefficient Of Variation(118.85)
Mean Deviation135.30
Median(153.29)
Standard Deviation191.61
Sample Variance36,714
Range596
R-Value0.50
Mean Square Error29,630
R-Squared0.25
Significance0.05
Slope19.99
Total Sum of Squares550,710

CODX Operating Margin History

2025 -10.75
2024 -10.24
2023 -6.27
2022 -0.34
2021 0.47
2020 0.56
2019 -27.42

About Co Diagnostics Financial Statements

Co Diagnostics investors use historical fundamental indicators, such as Co Diagnostics' Operating Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Co Diagnostics. Please read more on our technical analysis and fundamental analysis pages.
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection andor analysis of nucleic acid molecules in the United States and internationally. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Co Diagnostics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 101 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for CODX Stock Analysis

When running Co Diagnostics' price analysis, check to measure Co Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Co Diagnostics is operating at the current time. Most of Co Diagnostics' value examination focuses on studying past and present price action to predict the probability of Co Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Co Diagnostics' price. Additionally, you may evaluate how the addition of Co Diagnostics to your portfolios can decrease your overall portfolio volatility.